Table 2.
Risk factor analysis for transformation and POD24
| Transformation | POD24 | Transformation in POD24 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Not occurred | Occurred | P | Not occurred | Occurred | P | POD24 | T + POD24 | P | |
| Parameters, N (%) | 286 (88.3) | 38 (11.7) | 266 (82.1) | 58 (17.9) | 29 (50) | 29 (50) | |||
| Age ≥ 60 years | 58 (20.3) | 12 (31.6) | 0.140 | 57 (21.4) | 13 (22.4) | 0.861 | 5 (17.2) | 8 (27.6) | 0.530 |
| B-symptoms | 23 (8.0) | 3 (7.9) | 0.182 | 19 (7.1) | 7 (12.1) | 0.415 | 4 (13.8) | 3 (10.3) | 0.375 |
| Hemoglobin < 12 g/dL | 38 (13.3) | 14 (36.8) | 0.001 | 37 (13.9) | 15 (25.9) | 0.030 | 4 (13.8) | 11 (37.9) | 0.070 |
| Elevated LDH | 47 (16.4) | 13 (34.2) | 0.013 | 40 (15.0) | 20 (34.5) | 0.001 | 9 (31) | 11 (37.9) | 0.783 |
| Elevated β2m | 65 (22.7) | 14 (36.8) | 0.004 | 58 (21.8) | 21 (36.2) | 0.006 | 10 (34.5) | 11 (37.9) | 0.477 |
| Nodal site ≥ 5 | 127 (44.4) | 16 (42.1) | 0.863 | 114 (42.9) | 29 (50.0) | 0.381 | 16 (55.2) | 13 (44.8) | 0.600 |
| Bulky mass | 23 (8.0) | 3 (7.9) | > 0.999 | 21 (7.9) | 5 (8.6) | 0.793 | 2 (6.9) | 3 (10.3) | >0.999 |
| BM involvement | 140 (49.0) | 16 (42.1) | 0.301 | 126 (47.4) | 30 (51.7) | 0.615 | 17 (58.6) | 13 (44.8) | 0.168 |
| Grade 3A | 78 (27.3) | 15 (39.5) | 0.129 | 74 (27.8) | 19 (32.8) | 0.522 | 6 (20.7) | 13 (44.8) | 0.092 |
| FLIPI ≥ 3 | 65 (22.7) | 16 (42.1) | 0.020 | 58 (21.8) | 23 (39.7) | 0.005 | 11 (37.9) | 12 (41.4) | 0.446 |
| Stage III/IV | 218 (76.2) | 35 (92.1) | 0.035 | 201 (75.6) | 52 (89.7) | 0.022 | 26 (89.7) | 26 (89.7) | >0.999 |
Abbreviations: POD24, progression of disease within 24 months; LDH, lactate dehydrogenase; β2m, β2-microglobulin; BM, bone marrow; FLIPI, Follicular Lymphoma International Prognostic Index; T, transformation.